HKU Scholars Hub: Browsing DSpace

Browsing by Author Brown, N

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 2 to 19 of 19 < previous

	Title	Author(s)	Issue Date	Views
	Effect of core promoter/precore mutation pattern and early virologic response on efficacy outcomes with telbivudine in HBeAg-negative chronic hepatitis B Proceeding/Conference:Journal of Hepatology	Naoumov, N Lai, CL Gane, E Liaw, YF Thongsawat, S Wang, YM Heathcote, EJ Rasenack, J Bzowej, N Chao, G Brown, N	2006	137
	HBV resistance determination from the telbivudine globe registration trial Proceeding/Conference:Journal of Hepatology	Standring, DN Seifer, N Patty, A Chapron, C Van Doorn, LJ Chao, G Brown, N Lai, CL	2006	110
	Maximal Early Hbv Suppression In Nucleoside-treated Hepatitis B Patients Is Associated With Optimal Virologic And Clinical Efficacy At One Year Journal:Journal of Clinical Virology	Lim, SG Lai, CL Thongsawat, S Wang, Y Chen, Y Rasenack, J Naoumov, N Chao, G Brown, N	2006	97
	Maximal early HBV suppression is predictive of optimal virologic and clinical efficacy in nucleoside-treated hepatitis B patients: scientific observations from a large multinational trial (the GLOBE study) Proceeding/Conference:Hepatology	Lai, CL Gane, E Liaw, YF Thongsawat, S Wang, YM Chen, Y Heathcote, J Rasenack, J Bzowej, N Naoumov, N Chao, G Fielman, B Brown, N the GLOBE Study Group	2005	112
	NVR 3-778, a first-in-class HBVCORE inhibitor, alone and incombination with Peg-interferon (PEGIFN), in treatment naive HBeAg-Positive patients: early reductions in HBV DNA and HBeAg Proceeding/Conference:Journal of Hepatology	Yuen, RMF Kim, DJ Weilert, F Chan, HLY Lalezari, JP Hwang, SG Nguyen, T Liaw, S Brown, N Klumpp, K Flores, O Hartman, G Gane, E	2016	130
	Optimal virologic and clinical efficacy at one year is associated with maximal early HBV suppression in nucleoside-treated hepatitis B patients Proceeding/Conference:Journal of Hepatology	Zeuzem, S Lai, CL Gane, E Liaw, YF Thongsawat, S Wang, YM Chen, Y Heathcote, J Rasenack, J Bzowej, N Naoumov, N Chao, G Fielman, B Brown, N	2006	128
	Pharmacokinetics (PK) and PK modeling of the first-in- class HBV core inhibitor NVR 3-778 dosed once- (QD) or twice daily (BD) in healthy volunteers (HVs) and HBeAg-positive patients witn chronic HBV infection (CHBV) Proceeding/Conference:Hepatology	Kakuda, T Del Bene, E Yuen, RMF Gane, EJ Kim, S Liaw, S Brown, N Klumpp, K Flores, F Chanda, S	2016	74
	Phase III comparison of telbivudine vs lamivudine in HBeAg-positive patients with chronic hepatitis B: Efficacy, safety, and predictors of response at 1 year Proceeding/Conference:Journal of Hepatology	Gane, E Lai, CL Liaw, YF Thongsawat, S Wang, YM Cheng, Y Heathcote, J Rasenack, J Bzowej, N Naoumov, N Chao, G Fielman, B Brown, N	2006	119
	Phase III Comparison of Telbivudine vs Lamivudine in Patients with Chronic Hepatitis B: Efficacy, Safety, and Predictors of Response at 1 Year Proceeding/Conference:Gastroenterology	Bzowej, N Lai, CL Gane, E Liaw, Y Thongsawat, S Wang, Y Chen, Y Heathcote, J Rasenack, J Naoumov, N Chao, G Fielman, B Brown, N	2006	115
	Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B Journal:Clinical Infectious Diseases	Lai, CL Dienstag, J Schiff, E Leung, NWY Atkins, M Hunt, C Brown, N Woessner, M Boehme, R Condreay, L	2003	139
	A Randomized Trial of Telbivudine (LdT) vs Adefovir for HBeAg-positive Chronic Hepatitis B: Results of the Primary Week 24 Analysis Proceeding/Conference:Gastroenterology	Heathcote, EJ Chan, HL Cho, M Lai, CL Moon, YM Chao, YC Myers, R Minuk, G Marcellin, P Jeffers, L Sievert, W Kaiser, R Chao, G Brown, N	2006	120
	A randomized trial of telbivudine (LDT) vs. adefovir for HBeAg-positive chronic hepatitis B: Results of the primary week 24 analysis Proceeding/Conference:Journal of Hepatology	Chan, HLY Lai, CL Cho, M Heathcote, J Moon, Y-M Chao, Y-C Myers, R Minuk, G Marcellin, P Jeffers, L Sievert, W Kaiser, R Chao, G Brown, N	2006	132
	Results of a One-year International Phase IIB Comparative Trial of Telbivudine, Lamivudine, and the Combination, in Patients with Chronic Hepatitis B Proceeding/Conference:Hepatology	Lai, CL Leung, NWY Teo, EK Tong, M Wong, F Hann, HW Han, S Poynard, T Myers, M Chao, G Lloyd, D Brown, N	2003	157
	Safety and Antiviral Effects of Val-LdC and LdT in Patients with Chronic Hepatitis B Proceeding/Conference:Asian Pacific Association for the Study of the Liver Meeting	Lim, SG Young, DY Yuen, MF Myers, M Lloyd, D Brown, N Lai, CL	2002	97
	Safety, tolerability, pharmacokinetics and antiviral activity of AL-3778, a first-in-class, HBV core assembly modulator alone and in combination with peginterferon-alpha 2A, in treatment naive HBeAg-positive chronic hepatitis B patients Proceeding/Conference:Hepatology International	Kennedy, W Yuen, RMF Kim, DJ Weilert, F Chan, HLY Lalezari, J Hwang, SG Nguyen, T Westland, C Kakuda, T Brown, N Klumpp, K Flores, L Talloen, W Lenz, O Gane, E van Remoortere, P Chandra, S Fry, J	2017	81
	Telbivudine (LdT) vs. lmivudine for chronic Hepatitis B: First-year results from the international phase III GLOBE trial Proceeding/Conference:Hepatology	Lai, CL Gane, E Liaw, YF Thongsawat, S Wang, YM Chen, Y Heathcote, J Rasenack, J Bzowej, N Naoumov, N Chao, G Fielman, B Brown, N and the GLOBE Study Group, .	2005	97
	Telbivudine displays consistent antiviral efficacy across patient subgroups for the treatment of chronic hepatitis B: Results from the GLOBE study Proceeding/Conference:Journal of Hepatology	Thongsawat, S Lai, CL Gane, E Chao, G Fielman, B Brown, N GLOBE Investigator Group, .	2006	101
	Val-LdT: First evidence of efficacy and safety for a new anti-HBV agent Proceeding/Conference:Digestive Disease Week	Lim, SG Lai, CL Yuen, RMF Brown, N Lloyd, D Myers, M	2002	105

Showing results 2 to 19 of 19 < previous